EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

• The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten.
• Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy.
• The transaction is expected to close in the third quarter of 2026.

Shares of Edgewise Therapeutics (EWTX) soared more than 20% on Monday, climbing to record high, after French drugmaker Servier unveiled a multibillion-dollar deal to acquire the company’s muscular dystrophy business.

EWTX shares could clock their biggest single-day gains in more than six months if the stock closes at current levels.

EWTX To Receive $1.55B Upfront

On Monday, Servier expanded its footprint in rare neuromuscular disorders through a $2.65 billion deal to acquire Edgewise Therapeutics’ muscular dystrophy business, including programs targeting Becker and Duchenne muscular dystrophies.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones. The transaction is expected to close in the third quarter of 2026.

EWTX’s Sevasemten In Spotlight

The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten. The investigational oral therapy is designed to protect fragile muscles from contraction-related damage in patients with rare muscular dystrophies.

Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy (BMD) and a Phase 2 study for Duchenne muscular dystrophy (DMD). There are currently no approved treatments for BMD, a rare genetic disorder that causes progressive muscle weakness and loss of function.

“This transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support its continued development for people living with Becker and Duchenne muscular dystrophies,” said Kevin Koch, CEO of Edgewise Therapeutics.

Sevasemten Shows Strong Safety Profile

Edgewise’s MESA extension study is currently evaluating the long-term safety and effectiveness of Sevasemten in patients with Becker muscular dystrophy.

According to data presented at the 2026 MDA Clinical and Scientific Conference in March, patients maintained stable physical function for up to 3.5 years, compared with the decline typically seen in the disease. The drug also demonstrated a favorable cardiac safety profile over 12 months, with signs of improved cardiac function in some patients.

EWTX Sentiment Remains Bullish

Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.

One user noted that upon completion of the deal, Edgewise will become a cardiovascular-focused company.

The stock has gained around 30% so far this year.

Read also: GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial

For updates and corrections, email newsroom[at]stocktwits[dot]com.